Do SARMs Need a PCT? The Honest Answer

The "no-suppression SARM" myth

The original sales pitch around SARMs for the general public leaned for years on the idea of anabolic activity 'without the side effects of steroids' — including no HPTA suppression. That framing is commercial, not pharmacological. Any ligand that activates the androgen receptor with substantial efficacy is going to trigger negative feedback on the hypothalamus and pituitary: that is exactly what happens with anabolic SARMs at the doses used in practice.

The available clinical studies, case literature and community feedback all converge: anabolic SARMs suppress LH/FSH secretion and therefore endogenous testosterone production, at a level that depends on the compound, dose and duration ^[3]. Compared to a steroid cycle, suppression is broadly less deep and recovery often faster — but it exists and gets measured.

Real suppression, compound by compound

Ostarine

Ostarine is the best-tolerated SARM. At beginner doses (10-15 mg/day) over 6 to 8 weeks, suppression is mild and recovery usually happens on its own in the weeks following the stop ^[2]. At intermediate doses (20-25 mg/day) or on longer cycles, suppression becomes measurable and a mini-PCT (Nolvadex 20 mg/day for 4 weeks) secures the recovery. See the Ostarine compound page for the full ranges.

LGD-4033

LGD-4033 (Ligandrol) is the most anabolic SARM in practice — with suppression to match. From 5 mg/day over a few weeks, endogenous testosterone drops significantly and LH/FSH collapse in the majority of users ^[1]. A full PCT on the steroid model (Nolvadex 40/40/20/20 or 20/20/20/20) is the prudent approach. See the LGD-4033 compound page.

RAD-140

RAD-140 (Testolone) is positioned as "the most powerful SARM" and suppression matches that potency. From 10 mg/day, HPTA suppression is marked and durable. Full PCT recommended, at the dose and duration of a contained steroid cycle. See the RAD-140 compound page.

Mini-PCT vs full PCT: what changes

Mini-PCT (mild Ostarine or confirmed light suppression)

• Nolvadex 20 mg / day for 4 weeks.
• Or Clomid 25 mg / day for 4 weeks for users who prefer Clomid.
• Start: 24 to 48 hours after the last SARM dose (SARMs have short half-lives).
• No HCG needed — central suppression is too short to have caused significant testicular atrophy.

Full PCT (LGD-4033, RAD-140, long cycles or high doses)

• Nolvadex 40/40/20/20 (or 20/20/20/20 if tolerance is limited) over 4 weeks.
• Clomid 50/50/25/25 as an alternative for severe suppression.
• Start: 1 to 2 days after the last dose (depending on the SARM half-life — see compound page).
• Follow-up blood panel 4 to 6 weeks after PCT ends, same as for a steroid cycle.

These protocols rely on clinically-validated SERM schemes for post-androgenic hypogonadism ^[4]. For each protocol in detail, see Nolvadex vs Clomid. Start timing is simpler than for steroid esters (SARM half-lives are measured in hours, not days), but the logic stays the same: wait until peripheral signal fades for the SERMs to have traction.

Blood work: what settles mini-PCT vs full PCT

The factor that actually distinguishes a mini-PCT from a full PCT is not the compound in theory — it is the actual suppression on bloods. Two users on the same Ostarine 25 mg/day for 8 weeks can finish with a testosterone of 600 ng/dL for one and 200 ng/dL for the other. Individual sensitivity varies a lot.

Recommended schedule for a SARMs cycle

• Baseline before the cycle: total and free testosterone, LH, FSH, estradiol. Done once — that is your personal reference.
• End-of-cycle panel (just before the last dose or in the days following): to measure actual suppression and pick mini-PCT or full PCT on the basis of that read.
• Blood panel 4 to 6 weeks after PCT ends: confirm recovery.

Detail in hormonal markers on cycle and blood test schedule on cycle.

Common mistakes on SARMs PCT

• No PCT "because it is just a SARM" — true for MK-677 and Cardarine, false for LGD-4033 and RAD-140, case-by-case for Ostarine.
• Default mini-PCT with no bloods — risk of under-treating marked suppression and dragging out the hypogonadism window.
• Using another SARM as a "bridge" between cycle and PCT — practice sometimes wrongly advised. It maintains androgenic activation and prevents the restart from getting off the ground.
• Running a full PCT without a baseline — you cannot judge recovery without knowing the starting point. The post-PCT panel has to be read against a personal baseline.
• Confusing PCT with "OTC PCT" (supplements marketed as restarts). Those products have never demonstrated hormonal effects comparable to SERMs in the literature. For measurable suppression, it is Nolvadex or Clomid — not a supplement.

Frequently asked questions